scholarly article | Q13442814 |
P356 | DOI | 10.1038/NBT0910-879 |
P953 | full work available at URL | http://www.nature.com/articles/nbt0910-879.pdf |
http://www.nature.com/articles/nbt0910-879 | ||
P698 | PubMed publication ID | 20829807 |
P2093 | author name string | Malorye Allison | |
P2860 | cites work | Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 |
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer | Q43111250 | ||
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients | Q46464385 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 879-880 | |
P577 | publication date | 2010-09-01 | |
P1433 | published in | Nature Biotechnology | Q1893837 |
P1476 | title | Avastin's commercial march suffers setback | |
P478 | volume | 28 |
Q37963955 | Benefit-risk assessment of bevacizumab in the treatment of breast cancer. |
Q36248498 | Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence |
Q83161956 | Can cancer clinical trials be fixed? |
Q38003390 | Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions |
Search more.